Lähteenmäki P, Weiner E, Lähteenmäki P, Johansson E, Luukkainen T
Contraception. 1981 Jan;23(1):63-75. doi: 10.1016/0010-7824(81)90115-3.
An RIA for a new progestin, ST-1435, was developed. Plasma concentrations of this steroid were measured in three women having three subcutaneous capsules, each containing 40 mg of ST-1435. Pituitary and ovarian functions were assessed by measuring plasma levels of LH, FSH, estradiol and progesterone. Plasma profiles of ST-1435 were characterized by high and irregular peaks all the way through the study period of 7-9 months. Concentrations below 100 pg/ml were not observed, whereas the highest peaks reached concentrations of 10.1 ng/ml. Plasma estradiol concentrations remained uniformly suppressed below 100 pg/ml, thus indicating a suppression in follicle development. As judged by constantly suppressed progesterone concentrations, no ovulations occurred during the treatment. Plasma FSH concentrations remained at the upper limit of the follicular phase, and those of LH at the lower limit of the luteal phase of the normal menstrual cycle. No midcycle gonadotropin peaks were observed.
开发了一种针对新型孕激素ST - 1435的放射免疫分析方法。对三名女性进行了该类固醇血浆浓度的测定，这三名女性每人植入了三个皮下胶囊，每个胶囊含有40毫克ST - 1435。通过测量血浆中促黄体生成素（LH）、促卵泡生成素（FSH）、雌二醇和孕酮的水平来评估垂体和卵巢功能。在整个7至9个月的研究期间，ST - 1435的血浆浓度呈现出高且不规则的峰值。未观察到浓度低于100皮克/毫升的情况，而最高峰值达到了10.1纳克/毫升。血浆雌二醇浓度一直被抑制在100皮克/毫升以下，这表明卵泡发育受到抑制。从持续被抑制的孕酮浓度判断，治疗期间未发生排卵。血浆FSH浓度保持在正常月经周期卵泡期的上限，而LH浓度则保持在黄体期的下限。未观察到月经周期中期促性腺激素峰值。
